Benzimidazol derivatives modulate chemokine receptors

Details Benzimidazol derivatives modulate chemokine receptors Benzimidazol derivatives modulate chemokine receptors

2008-06-17

2008-06-17

Chang, Celia (Department: 1625)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S318000, C514S321000, C546S193000, C546S197000, C546S199000

Reexamination Certificate

active

07388020

ABSTRACT:
The invention provides compounds of general formula (I) wherein A, X, m, R1, N, R2, Z1, Z2, Q, R3, R4, R5, R6, R7, R8, t and R16are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy

REFERENCES:
patent: 3203992 (1965-08-01), Kunz et al.
patent: 3577432 (1971-05-01), Helsley et al.
patent: 3755584 (1973-08-01), Plotnikoff et al.
patent: 3818017 (1974-06-01), Janssen et al.
patent: 3894030 (1975-07-01), Janssen et al.
patent: 4029801 (1977-06-01), Cavalla et al.
patent: 4080328 (1978-03-01), Maruyama et al.
patent: 4166119 (1979-08-01), Effland et al.
patent: 4264613 (1981-04-01), Regnier et al.
patent: 4304915 (1981-12-01), Berthold
patent: 4338323 (1982-07-01), Regnier et al.
patent: 5576321 (1996-11-01), Krushinski, Jr. et al.
patent: 5614523 (1997-03-01), Audia et al.
patent: 5614533 (1997-03-01), Anderson et al.
patent: 5627196 (1997-05-01), Audia et al.
patent: 5741789 (1998-04-01), Hibschman et al.
patent: 5789402 (1998-08-01), Audia et al.
patent: 6911458 (2005-06-01), Eriksson et al.
patent: 6927222 (2005-08-01), Hansen et al.
patent: 6943188 (2005-09-01), Eriksson et al.
patent: 6951874 (2005-10-01), Hansen et al.
patent: 7005439 (2006-02-01), Eriksson et al.
patent: 2005/0090494 (2005-04-01), Eriksson et al.
patent: 2005/0239801 (2005-10-01), Eriksson et al.
patent: 37 23 568 (1989-01-01), None
patent: 37 23 648 (1989-01-01), None
patent: 197 03 131 (1998-07-01), None
patent: 197 55 268 (1999-06-01), None
patent: 0 095 454 (1983-11-01), None
patent: 0 128 007 (1984-12-01), None
patent: 0 496 691 (1992-07-01), None
patent: 0 587 311 (1994-03-01), None
patent: 0 722 941 (1996-07-01), None
patent: 0 903 349 (1999-03-01), None
patent: 2 190 430 (1974-02-01), None
patent: 1368012 (1974-09-01), None
patent: WO 93/25528 (1993-12-01), None
patent: WO 97/23458 (1997-07-01), None
patent: WO 98/32442 (1998-07-01), None
patent: WO 99/25686 (1999-05-01), None
patent: WO 99/31092 (1999-06-01), None
patent: WO 99/65895 (1999-12-01), None
patent: WO 00/35449 (2000-06-01), None
patent: WO 00/35451 (2000-06-01), None
patent: WO 00/53600 (2000-09-01), None
patent: WO 00/58305 (2000-10-01), None
patent: WO 00/69820 (2000-11-01), None
patent: WO 01/14333 (2001-03-01), None
patent: WO 01/43744 (2001-06-01), None
patent: WO 01/44227 (2001-06-01), None
patent: WO 01/87839 (2001-11-01), None
Berthold 3-aminopropoxyayl . . . CA 93:8015 (1980).
Tanabe et al. “Propanol . . . ” CA 96:110143 (1982).
Timmermans Hypotensive properties . . . CA 97:33112 (19820.
Levine beta2 adrenergic mechanisms . . . CA 109:52680.
Mizuhashi “A guinea pig model . . . ” CA 122:71729 (1995).
Chou et al. “Adrenergic regulation . . . ” CA 129:3784 (1998).
Wright et al. Subtype selective . . . CA 133:570800 (2000).
Exhibit A CAS search result.
Zenitz et al. “3-piperidino-loweralkyl indoles” CA 87:102164 (1977).
Matsuo et al. “preparation of N-pentadienoylaminoalkyl . . . ” CA 115:232091 (1991).
Tanaka et al. “Antiallergic aeffects of novel compounds SWR-00151” CA 126:311929 (1997).
Alcaraz et al. “Preparat of piperidinyl alcohols . . . ” CA 139:197375 (2003).
Bechtloff et al. “Pseudopolymorphs in industrial use” SciSearch 10289666 (2001).
Black et al. “Increased chemical purity . . . ” Scisearch 12765805 (2004).
Hu et al. “Dependence of the chemical dynamics . . . ” Beistein Abs. 5809171 (1993).
Katritzky et al. “Heterocyclic Chemistry” Cambridge, p. 75 (1964).
Saeki “molecular mechanism of reheumatoid . . . ” CA 125:272100 (1996).
Yamamoto :Espression of monocyte . . . CA 127:64176 (1997).
Schmidt et al. “Immune mechanisms . . . ” J. Allergy Clin, Immunol. April p. 673-682 (2000).
Eriksson et al. “Preparation of benzimidazole . . . ” CA 137:247698 (2002).
U.S. Appl. No. 10/204,754, filed Aug. 23, 2002, Hansen et al.
U.S. Appl. No. 10/204,789, filed Aug. 23, 2002, Hansen et al.
U.S. Appl. No. 10/204,790, filed Aug. 23, 2002, Bodkin et al.
U.S. Appl. No. 10/311,667, filed Dec. 17, 2002, Eriksson et al.
U.S. Appl. No. 10/311,841, filed Dec. 17, 2002, Eriksson et al.
U.S. Appl. No. 10/468,179, filed Aug. 18, 2003, Brough et al.
U.S. Appl. No. 10/472,017, filed Sep. 19, 2003, Eriksson et al.
Archibald et al., “Antiinflammatory 4-acylaminopiperidines”,CAPLUS77:34355 (1972).
Cattanach et al., “Studies in the Indole Series. Part IV. Tetrahydro-1H-pyrido[4, 3-b]-indoles as Serotonin Antagonists”,J. Chem. Soc. C. 10:1235-1243 (1968).
Cohen et al., “Cytokine function: A study in biologic diversity”,CAPLUS125:31527 (1996).
Friebe et al., “Piperidinopropyl derivatives and pharmaceutical compositions containing them”,CAPLUS94:103172 (1981).
Hesselgesser et al., “Identification and Characterization of Small Molecule Functional Antagonists of the CCR1 Chemokine Receptor”,J. Biol. Chem. 273(25):15687-15692 (1998).
Howard et al., “Chemokines: progress toward identifying molecular targets for therapeutic agents”,Trends in Biotechnology14:46-51 (1996).
Manabu Hori Kim D. Janda, “A Soluble Polymer Approach to the “Fishing Out” Principle: Synthesis and Purification of β-Amino Alcohols”,J. Org. Chem. 63:889-894 (1998).
Komai et al., “Structure-Activity Relationships of HIV-1 PR Inhibitors Containing AHPBA-II. Modification of Pyrrolidine Ring at P1′ Proline”,Bioorganic&Medicinal Chemistry4(8):1365-1377 (1996).
Leclerc et al., “Derivatives Related to Betaxolol with I-and J-Adrenergic Activities”,Arzneim.-Forsch/Drug. Res. 35(11):1357-1367 (1985).
Meurer et al., “Discovery of potent human CCR5 antagonists for the treatment of HIV-1 infection—II.”,CAPLUS2000:331722 (2000).
Navas III et al., “The Design and Synthesis of a Hapten for 1192U90, A Potential Atypical Antipsychotic Agent”,Synthetic Communications26(7):1411-1421 (1996).
Payard et al., “N-Aminomethylated Derivatives of Som eHydroxamic Acids as Anti-Inflammatories”,Eur. J. Med. Chem. pp. 1-10 (1975).
Rubini et al., “Synthesis of Isosteric Methylene-Oxy Pseudodipeptide Analogues as Novel Amide Bond Surrogate Units”,Tetrahedron42(21):6039-6045 (1986).
STN Int'l,CAPLUS1968.402884.
Timmermans et al., “Hypotensive Properties of Benzodioxane Derivatives Structurally Related to R 28935. Comparison to Activity with some Receptor Affinities”,Arch. int. Pharmacodyn. 255:321-334 (1982).
Wright et al., “Discovery of Selective Dopamine D4 Receptor Antagonists: 1-Aryloxy-3-(4-Aryloxypiperidinyl)-2-Propanols”,Bioorganic&Medicinal Chemistry Letters7(11):1377-1380 (1997).
Eriksson et al., “Preparation of substituted 1-benzyl-4-piperidinamines as chemokine receptor modulators”,CAPLUS136:69740 (2001).
Hansen et al., “Preparation of substituted 1-phenoxy-3-pyrrolidino(or piperidino)propan-2-ols as chemokine receptor modulators”, CAPLUS 135:195501 (2001).
Rollins, “Chemokines”, Blood 90(3):909-928 (1997).
Barnes et al., “COPD: is there light at the end of the tunnel?”,Curr Opin Pharmacol4:263-272 (2004).
Barnes et al., “Prospects for new drugs for chronic obstructive pulmonary”,Lancet364:985-996 (2004).
de Boer, “Potential new drugs for therapy of chronic obstructive pulmonary disease”,Expert Opin. Investig. Drugs12:1067-1086 (2003).

Affiliated with

Also associated with

Rating

Benzimidazol derivatives modulate chemokine receptors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Benzimidazol derivatives modulate chemokine receptors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Benzimidazol derivatives modulate chemokine receptors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2811579